Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis.
To clarify whether adding E(2) to standard luteal P supplementation is beneficial both in GnRH agonist and antagonist IVF cycles. Meta-analysis of nine randomized controlled trials. University hospital center for reproductive medicine and IVF. None. Clinical pregnancy rate (PR) per patient, clinical PR per embryo transfer (ET), implantation rate, ongoing PR per patient, clinical abortion rate, and ectopic PR. There were no statistically significant differences between E(2)+P versus P-only group regarding overall IVF outcomes. From seven studies including GnRH agonist cycles, no statistical significant differences were found between the two groups in clinical PR per patient (relative risk [RR] 1.32, 95% confidence interval [CI] 0.79-2.19), clinical PR per ET (RR 1.83, 95% CI 0.96-3.49), implantation rate (RR 1.20, 95% CI 0.34-4.21), ongoing PR per patient (RR 1.34, 95% CI 0.37-4.82), clinical abortion rate (RR 1.05, 95% CI 0.48-2.28), and ectopic PR (RR 0.53, 95% CI 0.07-4.10). Clinical PR per patient (RR 0.94, 95% CI 0.62-1.42) and ongoing PR per patient (RR 1.09, 95% CI 0.79-1.50) from three studies including GnRH antagonist cycles only were all similar between the two groups. The combined data presented in this meta-analysis suggest that the addition of E(2) to P for luteal phase support does not improve IVF outcomes in GnRH agonist and antagonist cycles. However, the authors feel that there is an obvious need for further large-scale studies regarding GnRH antagonist cycles.